Ireland-headquartered drugmaker Shire (LSE: SHP) has received acceptance for its filing with priority review a supplemental New Drug Application for Vyvanse (lisdexamfetamine dimesylate) as a treatment for adults with binge-eating disorder.
The US Food and Drug Administration is expected to make its decision in February 2015, based on the anticipated Prescription Drug User Fee Act action date. Vyvanse is currently approved for attention-deficit hyperactivity disorder (ADHD) only, and Shire is seeking approval for the drug as treatment for binge-eating based on the results of two randomized placebo-controlled Phase III studies.
Phil Vickers, head of R&D at Shire, said: “The decision from the FDA to accept our filing for priority review not only marks progress in the development of Vyvanse for adults with BED, but underscores this is an area of unmet medical need as there are currently no approved pharmacologic options for these patients.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze